<DOC>
<DOCNO>EP-0655462</DOCNO> 
<TEXT>
<INVENTION-TITLE>
Linear adhesion inhibitors
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K3807	A61P4300	C07K1700	C07K5103	C07K706	A61K3806	C07K100	A61P910	A61K3810	A61P702	A61P3500	A61K3816	C07K5093	A61P3500	C07K122	C07K1113	C07K5062	A61K3807	A61K3800	A61K3800	C07K5072	C07K1702	A61P908	C07K5113	C07K1400	C07K1475	C07K500	A61P700	C07K14435	A61K3805	C07K708	A61P900	A61K3805	C07K700	A61K3808	A61K3810	C07K1446	A61P2900	A61K3806	A61K3816	A61P2900	A61K3808	A61P900	A61P4300	C07K5083	C07K1400	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	C07K	C07K	C07K	A61K	C07K	A61P	A61K	A61P	A61P	A61K	C07K	A61P	C07K	C07K	C07K	A61K	A61K	A61K	C07K	C07K	A61P	C07K	C07K	C07K	C07K	A61P	C07K	A61K	C07K	A61P	A61K	C07K	A61K	A61K	C07K	A61P	A61K	A61K	A61P	A61K	A61P	A61P	C07K	C07K	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K38	A61P43	C07K17	C07K5	C07K7	A61K38	C07K1	A61P9	A61K38	A61P7	A61P35	A61K38	C07K5	A61P35	C07K1	C07K1	C07K5	A61K38	A61K38	A61K38	C07K5	C07K17	A61P9	C07K5	C07K14	C07K14	C07K5	A61P7	C07K14	A61K38	C07K7	A61P9	A61K38	C07K7	A61K38	A61K38	C07K14	A61P29	A61K38	A61K38	A61P29	A61K38	A61P9	A61P43	C07K5	C07K14	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Linear peptides of the formula I  X-A-Cys(R
<
1
>
)-B-Z     I,  wherein A, B, R
<
1
>
, X and Z have the meaning indicated in Claim 1, are effective inhibitors of binding of the blood platelet integrin GP IIbIIIa (aIIbss3) to natural ligands and are suitable, inter alia, for the prophylaxis and the treatment of disorders of the circulation, in thrombosis, cardiac infarct, coronary heart disorders, arterio- and atherosclerosis, tumours, osteolytic disorders, and assist in wound healing processes.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
MERCK PATENT GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
MERCK PATENT GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
DIEFENBACH BEATE
</INVENTOR-NAME>
<INVENTOR-NAME>
FELDING-HABERMANN BRUNHILDE DR
</INVENTOR-NAME>
<INVENTOR-NAME>
JONCZYK ALFRED DR
</INVENTOR-NAME>
<INVENTOR-NAME>
RIPPMANN FRIEDRICH DR
</INVENTOR-NAME>
<INVENTOR-NAME>
DIEFENBACH, BEATE
</INVENTOR-NAME>
<INVENTOR-NAME>
FELDING-HABERMANN, BRUNHILDE, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
JONCZYK, ALFRED, DR.
</INVENTOR-NAME>
<INVENTOR-NAME>
RIPPMANN, FRIEDRICH, DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Linear peptides of the formula I having a minimum
length of 4 amino acid residues


X-A-Cys(R
1
)-B-Z

in which

X
is H or Ac,
A
is absent or is Asp or a peptide fragment selected
from a group consisting of Ala-Asp, Thr-Ala-Asp,

Lys-Thr-Ala-Asp, Lys-Thr-Ala-Asn, Lys-Thr-Gly-Asp,
Lys-Ala-Ala-Asp, Arg-Thr-Ala-Asp, Ser-Ala-Asp,

Gln-Ser-Ala-Asp, Gly-Lys-Thr-Ala-Asp,
Asn-Gly-Lys-Thr-Ala-Asp, Ile-Ser-Ala-Gly,

Arg-Ser-Ala-Gly, Cys-Asn-Gly-Lys-Thr-Ala-Asp;
Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp,

Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp,
Gly-Lys-Thr-Cys-Asp,

Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp,
Gly-Lys-Thr-Cys(Trt)-Asp,

Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp and
Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp,
B
is absent or is Ala, Arg, Asn, Asp, Cys, Gln, Glu,
Gly, His, Ile, Leu, Lys, Met, Orn, Phe, 4-Hal-Phe,

Pro, Ser, Thr, Trp, Tyr or Val or is an N-methylated
derivative of the amino acid residues mentioned, or

is a peptide fragment selected from a group
consisting of Pro-Arg, Pro-Arg-Asn, Pro-Arg-Asn-Pro,

Pro-Arg-Asn-Pro-His, Pro-Arg-Asn-Pro-His-Lys,
Pro-Arg-Asn-Pro-His-Lys-Gly, 

Pro-Arg-Asn-Pro-His-Lys-Gly-Pro,
Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala and

Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr,

in which only one of the residues A or B can be absent,

Z
is OH, OR
2
, NH
2
, NHR
2
 or NR 2 / 2,
R
1
is H, R
2
, Trt, Dpm or Bzl,
R
2
is alkyl of 1-6 carbon atoms,
Hal
is F, Cl, Br or I and
Ac
is alkanoyl of 1-10 carbon atoms, aralkanoyl of 8-10
carbon atoms or aroyl of 7-11 carbon atoms,

and their physiologically acceptable salts.
An enantiomer or a diastereomer of a compound of
the formula I according to Claim 1.
(a) H-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH;
(b) H-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH;
(c) H-Gly-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-OH;
(d) H-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-OH;
(e) H-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-Gly-OH;
(f) H-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-Arg-OH;
(g) H-Lys-Thr-Ala-Asp-Cys(Trt)-Pro-OH and
(h) H
3
C-CO-Asp-Cys(Trt)-Pro-Arg-Asn-Pro-His-Lys-OH.
Process for the preparation of a compound of the
formula I according to Claim 1 or of one of its salts,

characterized in that it is liberated from one of its
functional derivatives by treatment with a solvolysing or

hydrolysing agent or in that a compound of the formula II

X-M-OH

in which

M
is an amino acid residue or peptide radical selected
from a group consisting of

A, A-Cys(R
1
), Ala, Thr, Thr-Ala, Lys, Lys-Thr, Lys-Thr-Ala, Gly,
Lys-Thr-Ala-Gly, Gly-Lys, Gly-Lys-Thr, Gly-Lys-Thr-Ala,

Gly-Lys-Thr-Cys(R
1
), Asn, Asn-Gly, Asn-Gly-Lys, Lys-Ala, Lys-Ala-Ala, 
Asn-Gly-Lys-Thr, Asn-Gly-Lys-Thr-Ala, Cys, Cys-Asn, Cys-Asn-Gly, Arg,

Arg-Thr, Arg-Thr-Ala, Ser, Cys-Asn-Gly-Lys, Cys-Asn-Gly-Lys-Thr,
Cys-Asn-Gly-Lys-Thr-Ala, Ser-Ala, Tyr, Tyr-Cys, Tyr-Cys-Asn,

Tyr-Cys-Asn-Gly, Tyr-Cys-Asn-Gly-Lys, Gln, Gln-Ser, Gln-Ser-Ala,
Tyr-Cys-Asn-Gly-Lys-Thr, Tyr-Cys-Asn-Gly-Lys-Thr-Ala, Asp, Asp-Tyr,

Asp-Tyr-Cys, Asp-Tyr-Cys-Asn, Asp-Tyr-Cys-Asn-Gly, Ile, Ile-Ser,
Ile-Ser-Ala, Asp-Tyr-Cys-Asn-Gly-Lys, Asp-Tyr-Cys-Asn-Gly-Lys-Thr,

Arg-Ser, Arg-Ser-Ala, Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala, Asp-Asp,
Asp-Asp-Tyr, Asp-Asp-Tyr-Cys, Asp-Asp-Tyr-Cys-Asn,

Asp-Asp-Tyr-Cys-Asn-Gly, Asp-Asp-Tyr-Cys-Asn-Gly-Lys,
Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr,

Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala, Met, Met-Asp, Met-Asp-Asp,
Met-Asp-Asp-Tyr, Met-Asp-Asp-Tyr-Cys, Met-Asp-Asp-Tyr-Cys-Asn,

Met-Asp-Asp-Tyr-Cys-Asn-Gly, Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys,
Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr,

Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala, Asp-Met, Asp-Met-Asp,
Asp-Met-Asp-Asp, Asp-Met-Asp-Asp-Tyr, Asp-Met-Asp-Asp-Tyr-Cys,

Asp-Met-Asp-Asp-Tyr-Cys-Asn, Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly,
Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys,

Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr,
Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala, A-Cys(R
1
)-Pro,
A-Cys(R
1
)-Pro-Arg, A-Cys(R
1
)-Pro-Arg-Asn, A-Cys(R
1
)-Pro-Arg-Asn-Pro,
A-Cys(R
1
)-Pro-Arg-Asn-Pro-His, A-Cys(R
1
)-Pro-Arg-Asn-Pro-His-Lys,
A-Cys(R
1
)-Pro-Arg-Asn-Pro-His-Lys-Gly,
A-Cys(R
1
)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro,
A-Cys(R
1
)-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala,

in which A and R
1
 are as defined in Claim 1,

and

X
is as defined but is not hydrogen if A and therefore
M are absent, is reacted with an amino compound of

the formula III
H-Q-Z

in which

Z
is as defined and
Q
is an amino acid residue or peptide radical selected
from a group consisting of
 
B, Cys(R
1
)-B, Arg-Asn, Arg-Asn-Pro, Asn-Pro, Arg-Asn-Pro-His,
Asn-Pro-His, Pro-His, Arg-Asn-Pro-His-Lys, Asn-Pro-His-Lys,

Pro-His-Lys, His-Lys, Arg-Asn-Pro-His-Lys-Gly, Asn-Pro-His-Lys-Gly,
Pro-His-Lys-Gly, His-Lys-Gly, Lys-Gly, Arg-Asn-Pro-His-Lys-Gly-Pro,

Asn-Pro-His-Lys-Gly-Pro, Pro-His-Lys-Gly-Pro, His-Lys-Gly-Pro,
Lys-Gly-Pro, Gly-Pro, Arg-Asn-Pro-His-Lys-Gly-Pro-Ala,

Asn-Pro-His-Lys-Gly-Pro-Ala, Pro-His-Lys-Gly-Pro-Ala,
His-Lys-Gly-Pro-Ala, Lys-Gly-Pro-Ala, Gly-Pro-Ala, Pro-Ala,

Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr, Asn-Pro-His-Lys-Gly-Pro-Ala-Thr,
Pro-His-Lys-Gly-Pro-Ala-Thr, His-Lys-Gly-Pro-Ala-Thr,

Lys-Gly-Pro-Ala-Thr, Gly-Pro-Ala-Thr, Pro-Ala-Thr, Ala-Thr,
Gly-Asp-Cys(R
1
)-B, Thr-Gly-Asp-Cys(R
1
)-B, Asp-Cys(R
1
)-B,
Ala-Asp-Cys(R
1
)-B, Thr-Ala-Asp-Cys(R
1
)-B, Lys-Thr-Ala-Asp-Cys(R
1
)-B,
Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B, Asn-Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B,
Asn-Cys(R
1
)-B, Ala-Asn-Cys(R
1
)-B, Thr-Ala-Asn-Cys(R
1
)-B,
Cys-Asn-Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B, Ala-Ala-Asp-Cys(R
1
)-B,
Ser-Ala-Asp-Cys(R
1
)-B, Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B,
Gly-Cys(R
1
)-B, Ala-Gly-Cys(R
1
)-B, Ser-Ala-Gly-Cys(R
1
)-B,
Cys(Trt)-Asp-Cys(R
1
)-B, Thr-Cys(Trt)-Asp-Cys(R
1
)-B,
Lys-Thr-Cys(Trt)-Asp-Cys(R
1
)-B,
Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B,
Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B or
Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Ala-Asp-Cys(R
1
)-B

in which B and R
1
 are as defined in Claim 1,

and/or in that a free mercapto, hydroxyl or amino group
is alkylated

and/or a compound of the formula I according to Claim 1
is converted into one of its salts by treatment with an

acid or base.
Process for the preparation of pharmaceutical
formulations, characterized in that a compound of the

formula I according to Claim 1 and/or one of its physiologically
acceptable salts, together with at least one

solid, liquid or semiliquid excipient or auxiliary, is
brought into a suitable administration form.
Pharmaceutical formulation, characterized in that
it contains at least one compound of the general formula

I according to Claim 1 and/or one of its physiologically 
acceptable salts.
Use of compounds of the formula I according to
Claim 1 or of physiologically acceptable salts thereof

for the preparation of a medicament for combating
diseases.
Use of compounds of the formula I according to
Claim 1 for the preparation of immobilized ligands for

affinity column chromatography.
Use of compounds of the formula I according to
Claim 1 for the purification of integrins by affinity

chromatography.
</CLAIMS>
</TEXT>
</DOC>
